Vancomycin-resistant enterococcal infections in Korea

被引:13
作者
Kim, JM [1 ]
Song, YG [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
关键词
vancomycin-resistant enterococci; VRE; Korea;
D O I
10.3349/ymj.1998.39.6.562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Enterococci recently became the second-to-third most commonly isolated organism from nosocomial infections. Enterococci are intrinsically more resistant to many antimicrobial agents and often show acquired resistance to many antimicrobial agents including high-level aminoglycosides. With the increased use of vancomycin, vancomycin-resistant enterococci (VRE) has become an important nosocomial pathogen. In Korea. the proportion of VRE among all enterococcal isolates in most tertiary care hospitals has remained around 1% or teas, bur the rare of carriage of VRE is no longer low in some settings and recent observations of a sudden increase of VRE isolation in several hospitals in Korea suggests that VRE infection may become a serious problem in the near future. The most important considerations are that vancomycin-resistant genes may spread to other highly virulent genera, such as MRSA, and that there are no approved and convincing effective antibiotics for the treatment of VRE. Therefore, current efforts have concentrated on limiting the spread of these organisms within the hospital environment. Prudent else of antimicrobial agents and strict adherence to preventive measures such as aggressive communication, education and infection control practices are essential to control the spread of this organism. However, hospital infection control protocols and the laboratory support they require are costly in terms of space and supplies, as self as in personnel resources. These factors add further pressure to already stretched hospital budgets Nevertheless, policies or programs defining and managing VRE infection or colonization should be established and now is the time to enforce an overall management strategy against VRE.
引用
收藏
页码:562 / 568
页数:7
相关论文
共 32 条
[1]   Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations [J].
Aeschlimann, JR ;
Zervos, MJ ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2710-2717
[2]  
[Anonymous], 1995, MMWR Recomm Rep, V44, P1
[3]   Vancomycin-resistant Enterococcus - Detection, epidemiology, and control measures [J].
Boyce, JM .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (02) :367-&
[4]   COMPARISON OF DIFFERENT BETA-LACTAM-GLYCOPEPTIDE-GENTAMICIN COMBINATIONS FOR AN EXPERIMENTAL ENDOCARDITIS CAUSED BY A HIGHLY BETA-LACTAM-RESISTANT AND HIGHLY GLYCOPEPTIDE-RESISTANT ISOLATE OF ENTEROCOCCUS-FAECIUM [J].
CARON, F ;
PESTEL, M ;
KITZIS, MD ;
LEMELAND, JF ;
HUMBERT, G ;
GUTMANN, L .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (01) :106-112
[5]  
CHEONG HJ, 1998, KOREAN J INFECT DIS, V30, P10
[6]  
CHO AW, 1998, 38 INT C ANT AG CHEM, P277
[8]   Enterococci and vancomycin resistance [J].
French, GL .
CLINICAL INFECTIOUS DISEASES, 1998, 27 :S75-S83
[9]   Vancomycin-resistant enterococci [J].
Gin, AS ;
Zhanel, GG .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (06) :615-624
[10]  
Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477